(Q44181876)

30 November 2017

title

Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins (English)

1 reference

30 November 2017

Francis Paolucci

1

1 reference

30 November 2017

Marie-Christine Claviés

series ordinal

2

1 reference

30 November 2017

François Donat

series ordinal

3

1 reference

30 November 2017

José Necciari

series ordinal

4

1 reference

30 November 2017

publication date

1 January 2002

1 reference

Clinical Pharmacokinetics

30 November 2017

published in

1 reference

30 November 2017

volume

41 Suppl 2

1 reference

30 November 2017

page(s)

11-18

1 reference

Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials

30 November 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003088-200241002-00002

The pharmacokinetics of fondaparinux sodium in healthy volunteers

21 January 2018

1 reference

12 December 2020

Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery

1 reference

12 December 2020

Determination of the anti-factor Xa activity of the synthetic pentasaccharide SR 90107A/ORG 31540 and of two structural analogues.

1 reference

12 December 2020

New antithrombotic agents for the prevention and treatment of deep vein thrombosis

1 reference

12 December 2020

Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide

1 reference

12 December 2020

Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement

1 reference

12 December 2020

Bioanalytical method validation--a revisit with a decade of progress

1 reference

12 December 2020

Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/Org31540) with high affinity to antithrombin III in man

1 reference

12 December 2020

Comparison of two low-molecular-weight heparins for the prevention of postoperative venous thromboembolism after elective hip surgery. Reviparin Study Group

1 reference

12 December 2020

A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement

1 reference

12 December 2020

Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin

1 reference

12 December 2020

Problems in therapeutic drug monitoring: free drug level monitoring.

1 reference

12 December 2020

1 reference

12 December 2020

Molar antithrombin concentration in normal human plasma

1 reference

12 December 2020

1 reference

12 December 2020

Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases.

1 reference

12 December 2020

Structure and biological activity of heparin.

1 reference

12 December 2020

Plasma TFPI activity after intravenous injection of pentasaccharide (PS) and unfractionated heparin in rabbits

1 reference

12 December 2020

Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.

1 reference

12 December 2020

10.2165/00003088-200241002-00002

Identifiers

DOI

0 references

Dimensions Publication ID

1049173710

0 references

1 reference